Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Chester, United Kingdom
Countries of investment
  • United Kingdom
Investment stages
  • Pre-Seed
  • Seed
  • Series A
Industries
  • MedTech
  • Digital Health
About
Deepbridge Capital focuses on investing in early-stage technology and life sciences startups in the UK, particularly those working in medtech, digital health, and sustainability. They use tax-advantageous EIS and VCT investment structures to help accelerate the growth of these startups, providing not only capital but also expert guidance. Deepbridge places a strong emphasis on the ability of these companies to achieve near-term commercial traction and sustainable long-term growth, making sure the ventures they back have the right management teams and resources to thrive in competitive markets.
Min check size
$25K
Max check size
$20M
Fund size
NPS

Investment Thesis

Deepbridge Capital’s investment thesis is grounded in supporting innovation-driven early-stage companies that demonstrate strong market demand and scalable IP. Through EIS and VCT structures, the firm mitigates investor risk while enabling growth in key UK sectors such as medtech, renewable energy, and digital technology. Deepbridge backs management teams that combine technical depth with commercial acumen, emphasizing revenue generation and capital efficiency. Its goal is to foster sustainable businesses that can deliver strong returns while contributing positively to technological progress and economic resilience.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Led by a team with strong backgrounds in private equity and venture capital, combining sector expertise in tech, healthcare, and energy.

Deepbridge Capital Contacts Information

Primary contact

Secondary contact

Team

Ian Warwick- Managing Partner

Gareth Groome -ACA BFP Partner & Chief Financial Officer

Kieran O'Gorman -Technical Partner

Dr. Savvas Neophytou -Partner & Chief Investment Officer

Andrew Aldridge -Chief Operating Officer

Ben Carter Investment- Director

Head of Life Sciences

Fuchsia Curry -Commercial Director

Phillip Secrette- Operations Director

Anjali Roberts- Strategic Partnerships' Director

Ray Eugeni- Partner

Rick Parry-Partner Sandie Marshall- Finance Manager Senior Investment Team

Portfolio

AlgaeCytes

FinTech start-ups

sustainable tech

drug discovery

AI/VR

Blockchain

MedTech

agritech

therapeutics

health tech

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp